![](/images/graphics-bg.png)
An update on thalassemia intermedia
Joint Authors
Makarun, Juzif E.
Cappellini, Maria Domenica
Tahir, Ali T.
Source
Issue
Vol. 61, Issue 3 (30 Sep. 2013), pp.175-182, 8 p.
Publisher
Publication Date
2013-09-30
Country of Publication
Lebanon
No. of Pages
8
Main Subjects
Topics
Abstract EN
Thalassemia intermedia is a genetically diverse group of diseases that is the result of an imbalance in the production of the alpha and beta chains with ensuing chronic hemolysis, ineffective erythropoiesis, and iron overload.
Resulting complications include bone changes, hypercoagulability, and endorgan damage due to iron overload.
This decade has witnessed major breakthroughs in the management of thalassemia.
In this article, we examine these novelties in therapy including iron chelation therapy, stem cell transplant, and gene therapy.
Iron chelation therapy has been revolutionized with the advent of deferasirox, a once-daily oral iron chelator, that has been shown to be safe and efficacious.
Gene therapy was also at the core of this revolution with the discovery of novel gene elements and viral vectors allowing for better control and improved outcomes.-
American Psychological Association (APA)
Makarun, Juzif E.& Cappellini, Maria Domenica& Tahir, Ali T.. 2013. An update on thalassemia intermedia. Journal Médical Libanais،Vol. 61, no. 3, pp.175-182.
https://search.emarefa.net/detail/BIM-395676
Modern Language Association (MLA)
Makarun, Juzif E.…[et al.]. An update on thalassemia intermedia. Journal Médical Libanais Vol. 61, no. 3 (2013), pp.175-182.
https://search.emarefa.net/detail/BIM-395676
American Medical Association (AMA)
Makarun, Juzif E.& Cappellini, Maria Domenica& Tahir, Ali T.. An update on thalassemia intermedia. Journal Médical Libanais. 2013. Vol. 61, no. 3, pp.175-182.
https://search.emarefa.net/detail/BIM-395676
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 180-182
Record ID
BIM-395676